Sterling Capital Management’s ADMA Biologics ADMA Stock Holding History

Sterling Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.78K	Sell	810 -692	-46%	-$6.31K	﹤0.01%	2447
2026 Q1	$13.5K	Sell	1,502 -23	-2%	-$363	﹤0.01%	2216
2025 Q4	$27.8K	Buy	1,525 +963	+171%	+$16.2K	﹤0.01%	2059
2025 Q3	$8.24K	Buy	562 +2	+0.4%	+$34	﹤0.01%	2594
2025 Q2	$10.2K	Buy	560 +317	+130%	+$6.46K	﹤0.01%	2125
2025 Q1	$4.82K	Buy	243 +15	+7%	+$259	﹤0.01%	2184
2024 Q4	$3.91K	Sell	228 -1	-0.4%	-$19	﹤0.01%	2562
2024 Q3	$4.58K	Buy	+229	New	+$3.56K	﹤0.01%	1800

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Sterling Capital Management's ADMA Position: Q2 2026 in Review

Sterling Capital Management reduced its ADMA Biologics (ADMA) stake by 46% in Q2 2026, selling an estimated $6.31K and leaving 810 shares worth $6.78K. The position accounts for ﹤0.01% of the portfolio, ranked #2447.

Sterling Capital Management first reported a position in ADMA in Q3 2024 and has held it in 8 quarters since. The position peaked at $27.8K in Q4 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Sterling Capital Management held 810 shares of ADMA Biologics worth $6.78K as of Q2 2026.
Sterling Capital Management sold 692 ADMA Biologics shares in Q2 2026, an estimated $6.31K.
ADMA Biologics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2447 holding.
Sterling Capital Management first reported a position in ADMA Biologics in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's ADMA Biologics position peaked at $27.8K in Q4 2025.
323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.